Status:
COMPLETED
Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation
Lead Sponsor:
Ohio State University Comprehensive Cancer Center
Conditions:
Graft-Versus-Host Disease
Eligibility:
All Genders
20+ years
Phase:
PHASE2
Brief Summary
This study will evaluate the efficacy of infliximab in reducing the incidence of grade II-IV acute graft versus host disease by day +100 post-transplant in patients undergoing allogeneic hematopoietic...
Detailed Description
Rationale: Acute graft host disease (GvHD) remains a barrier to successful hematopoietic stem cell transplantation (HCT) used for the treatment of cancers in some patients. GvHD can result from a lack...
Eligibility Criteria
Inclusion
- Patients undergoing allogeneic HCT for the following disorders:
- Acute myelogenous leukemia
- Acute lymphoblastic leukemia
- Non-Hodgkin's lymphoma
- Hodgkin's disease
- Multiple myeloma
- Chronic lymphocytic leukemia
- Chronic myeloid leukemia in accelerated or blast crisis at time of transplant.
- Age \>20 yrs
Exclusion
- Patients undergoing allogeneic stem cell transplantation for chronic myelogenous leukemia and aplastic anemia are excluded.
- Pregnant or breast-feeding females.
Key Trial Info
Start Date :
February 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2008
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT00201799
Start Date
February 1 2004
End Date
March 1 2008
Last Update
June 10 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ohio State University
Columbus, Ohio, United States, 43210